Eric Shaff, Seres CEO
Nestlé is betting $525M on a bid to pioneer world's first microbiome drug
After fighting a years-long uphill battle with its oral microbiome candidate SER-109, Seres Therapeutics finally got the Phase III results it was looking for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
